Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
- Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg.
- The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.
- KRAKOW, Poland, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.
- “The results from the CLI120-001 (RIVER-51) study of RVU120 in patients with r/r-AML and HR-MDS continue to improve over time.